AbbVie’s Obesity Drug ABBV-295 Yields Up to 9.8% Weight Loss in Phase 1 Trial
AbbVie's Phase 1 trial of its obesity candidate ABBV-295 achieved mean weight losses of 7.75% to 9.79% at week 12 across 2–14 mg doses, with only mild gastrointestinal side effects. AbbVie shares slipped 0.25% on Monday despite noted increase in online investor activity.
1. Phase 1 Obesity Drug Outcomes
AbbVie's ABBV-295 trial enrolled participants at doses ranging from 2 mg to 14 mg and demonstrated mean body weight reductions of 7.75% to 9.79% at week 12, with mild gastrointestinal disorders as the primary adverse events. The program is being developed under a March 2025 licensing agreement with Gubra A/S.
2. Share Reaction and Investor Interest
On Monday, AbbVie shares slipped 0.25% during broader market declines (S&P 500 down 0.9%, Healthcare sector down 0.4%), while online investor activity tracking indicates elevated interest in the stock. The shares remain 0.4% above their 20-day simple moving average and 1.5% above their 100-day SMA, suggesting continued short-term strength.
3. Analyst Consensus and Targets
AbbVie carries a consensus Buy rating with an average price target of $241.24. Recent analyst actions include RBC Capital initiating Outperform at $260, Barclays starting Overweight at $275, and Piper Sandler raising its target to $299.